The Cardiovascular and Renal Drugs Advisory Committee (CRDAC), voted Thursday 7-4, with one abstention and much uncertainty, in favor of the FDA approving Northera from Chelsea Therapeutics International Inc. for treating neurogenic orthostatic hypertension (NOH) in patents with primary autonomic failure due to conditions such as Parkinson's disease, multiple system atrophy and pure autonomic failure, dopamine beta hydroxylase deficiency and nondiabetic autonomic neuropathy.